November 04, 2025

Get In Touch

Oral Probiotics And Topical Hydrocortisone May Reduce Severity Of Psoriasis

Psoriasis Study Findings

Psoriasis Study Findings

Psoriasis area severity index (PASI), Dermatology life quality index (DLQI), and visual analogue scale (VAS) were improved in psoriasis patients who received oral probiotics with topical hydrocortisone. The findings of the study were published in the Journal of Dermatology Research and Practice.

There has been a recent increase with regard to the oral administration of probiotics for the treatment of psoriasis. Oral probiotics have been known (previous research) to have a positive role in the treatment of psoriasis. Since the anti-inflammatory effect of the branded preprobiotics, Lactocare® on the severity of ulcerative colitis and also on the serum electrolytes and trace elements in psoriasis has previously been published, this study by Ali Akbarzadeh and peers aimed to evaluate the effect of oral probiotic on the treatment of psoriasis.

A total of 52 patients with psoriasis were randomly divided into treatment and placebo (control) groups. The control group received topical hydrocortisone along with placebo, whereas in the treatment group, Lactocare® was orally administrated along with hydrocortisone.

Findings of the Study

  • The mean value of VAS, DLQI, and PSAI were recorded and evaluated as pretreatment and post-treatment in both groups for a period of 3 months.
  • The mean of the values in the control groups were compared to the values in the treatment group.
  • Intragroup analysis was done comparing the mean of the scores at baseline, 4-weeks, 8-weeks, and 12-weeks post-treatment.
  • A significant reduction was noticed in the PASI, VAS, and DLQI scores 12 weeks post-treatment in the treatment group when compared to the control group.

Source

Akbarzadeh, A., Alirezaei, P., Doosti-Irani, A., Mehrpooya, M., & Nouri, F. (2022). The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. In C. G. Burkhart (Ed.), Dermatology Research and Practice (Vol. 2022, pp. 1–7). Hindawi Limited. https://doi.org/10.1155/2022/4549134

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!